Middle East Pharmaceutical Industries Company Receives Approval for Capital Increase

The Capital Market Authority (CMA) has officially authorized the capital increase request submitted by the Middle East Pharmaceutical Industries Company. The regulatory approval permits the firm to raise its capital by SAR 350,000,000.

To facilitate this increase, the company will issue bonus shares to its current shareholders. Under the approved structure, investors will receive three bonus shares for every four existing shares held in the company. This move is designed to capitalize a portion of the firm's reserves, effectively expanding its issued share capital.

The CMA noted that the distribution of these shares is intended for shareholders registered with the Securities Depository Center at the close of the second trading period following the company’s extraordinary general assembly meeting. The specific date for this meeting will be determined by the company's board of directors at a later time.

Following the completion of the issuance, Middle East Pharmaceutical Industries Company will be required to comply with all regulatory disclosures and corporate governance requirements mandated by the CMA. The company has confirmed that the increase will be executed through the capitalization of retained earnings and statutory reserves. Existing shareholders are advised to monitor official announcements regarding the record date for the bonus share distribution.